Skip to main content

Advertisement

Log in

Therapeutic outcome of dapagliflozin on various parameters in non-alcoholic fatty liver disease (NAFLD) patients

  • Original article
  • Published:
International Journal of Diabetes in Developing Countries Aims and scope Submit manuscript

Abstract

Background

Body weight reduction is the first-line recommendation in NAFLD patients. Dapagliflozin has a strong potential to reduce body weight in addition to its glycemic control effect

Objective

To study the effect of dapagliflozin on various parameters in NAFLD type 2 diabetic patients.

Methods

In this randomized controlled trial, 150 type 2 diabetic patients with NAFLD diagnosed on the basis of radiological findings and deranged liver enzymes were randomly allocated into two groups. Both groups were taking tab glimepiride as a standard treatment of type 2 diabetes. Group A was given tab dapagliflozin 5–10 mg while group B was given tab placebo in addition to lifestyle modifications for a period of 12 weeks. Body weight, BMI, HbA1c, and serum aminotransferases were analyzed pre- and post-treatment using SPSS 20.

Results

After 12 weeks of treatment, glycemic control was improved in both study groups, i.e., dapagliflozin (FBS from 95 ± 14 to 80 ± 11 mg/dl with p = 0.003, HbAIc from 7.5 ± 4.5 to 6.4 ± 5.4% with p = 0.002) and placebo (FBS from 100 ± 9.5 to 90.5 ± 13 mg/dl with p = 0.004, HbA1c from 8.2 ± 3.5 to7.6 ± 4.2% with p = 0.006). However, the dapagliflozin group showed a significant reduction in FBS and HbA1c as compared to placebo with p value 0.006 and 0.04 respectively. Body weight was significantly reduced in the dapagliflozin group (from 90 ± 13.5 to 84 ± 11.6) as compared to the placebo group (from 85 ± 17.8 to 85.5 ± 13.7) with p = 0.002. BMI also reduced in the dapagliflozin group (from 29.5 ± 2.5 to 26.5 ± 3.5) versus the placebo group (from 31.5 ± 3.0 to 29.5 ± 4.2) with p = 0.002. There was also significant reduction in ALT in the dapagliflozin group from 69 ± 15.5 to 52 ± 12.8 versus placebo from 68 ± 20.5 with p = 0.04 and AST from 74 ± 13 to 47 ± 13.5 versus placebo from 71 ± 12.5 to 65 ± 10.5 with p = 0.02

Conclusion

Dapagliflozin has a strong potential to reverse NAFLD-associated changes in type 2 diabetic patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

Data availability

Can be provided on request.

References

  1. Younossi ZM, Koenig AB, Abdelatif D, Fazel Y, Henry L, Wymer M. Global epideminiology of non alcoholic fatty liver disease- meta-analytic assessment of prevalence, incidence and outcomes. Hepatolgy. 2016;64(1):73–84. https://doi.org/10.1002/hep.28431.

    Article  Google Scholar 

  2. Ashtaris S, Pourhoseingholi MA, Zali MR. Non alcoholic fatty liver disease in Asia: prevention and planning. World J Hepatol. 2015;7(13):1788–96. https://doi.org/10.4254/wjh.v7.i13.1788.

    Article  Google Scholar 

  3. Lee YH, Cho Y, Lee BW, Park CY, Lee DH, Cha BS, Rhee EJ. Nonalcoholic fatty liver disease in diabetes. Part I: epidemiology and diagnosis. Diabetes Metab J. 2019;43(1):31–45. https://doi.org/10.4093/dmj.2019.0011.

    Article  PubMed  Google Scholar 

  4. Prat LI, Tsochatzis EA. The effect of antidiabetic medications on non-alcoholic fatty liver disease (NAFLD). Hormones. 2018;17(2):219–29. https://doi.org/10.1007/s42000-018-0021-9.

    Article  Google Scholar 

  5. Tacelli M, Celsa C, Magro B, Giannetti A, Pennisi G, Spatola F. Antidiabetic drugs in NAFLD: the accomplishment of two goals at once? Pharmaceuticals. 2018;11(4):121.

    Article  CAS  Google Scholar 

  6. Bonora BM, Avogaro A, Fadini GP. Extraglycemic effects of SGLT2 inhibitors: a review of the evidence. Diab Metab Syndr Obes: Targets Ther. 2020;13:161.

    Article  CAS  Google Scholar 

  7. Ghezzi C, Amy SY, Hirayama BA, Kepe V, Liu J, Scafoglio C. Dapagliflozin binds specifically to sodium-glucose co transporter 2 in the proximal renal tubule. J Am Soc Nephrol. 2017;28(3):802–10.

    Article  CAS  Google Scholar 

  8. Dokmak A, Almeqdadi M, Trivedi H, Krishnan S. Rise of sodium-glucose cotransporter 2 inhibitors in the management of nonalcoholic fatty liver disease. W J Hepatol. 2019;11(7):562.

    Article  Google Scholar 

  9. Yanai H, Hakoshima M, Katsuyama H. The possible mechanisms for improvement of liver function due to sodium-glucose cotransporter-2 inhibitors. J Clin Med Res. 2019;11(11):769.

    Article  Google Scholar 

  10. Pereira MJ, Eriksson JW. Emerging role of SGLT-2 inhibitors for the treatment of obesity. Drugs. 2019;79(3):219–30.

    Article  CAS  Google Scholar 

  11. Wong VW, Chan RS, Wong GL, Cheung BH, Chu WC, Yeung DK. Community based life style modification program for non alcoholic fatty liver disease: a randomized controlled trials. J Hepatol. 2013;59(3):536–42. https://doi.org/10.1016/j.jhep.2013.04.013.

    Article  PubMed  Google Scholar 

  12. Gomez EV, Perez YM, Berot LC, Gonzalez AT, Oramas BG, Fabian LG. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gasteroenterol. 2015;149(2):367–78. https://doi.org/10.1053/j.gastro.2015.04.005.

    Article  Google Scholar 

  13. Cai X, Yang W, Gao X, Chen Y, Zhou L, Zhang S, Han X, Ji L. The association between the dosage of SGLT2 inhibitor and weight reduction in type 2 diabetes patients: a meta-analysis. Obes. 2018;26(1):70–80.

    Article  CAS  Google Scholar 

  14. Choi DH, Jung CH, Mok JO, Kim CH, Kang SK, Kim BY. Effect of dapagliflozin on alanine aminotransferase improvement in type 2 diabetes mellitus with non-alcoholic fatty liver disease. Endocrinol Metab. 2018;33(3):387–94.

    Article  CAS  Google Scholar 

  15. Koutsovasilis A, Sotiropoulos A, Pappa M, Papadaki D, Kordinas V, Tamvakos C. The effect of lixisenatide and dapagliflozin in nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus compared with sitagliptin and pioglitazone. Diabetes. 2018;67(Supplement 1). .https://doi.org/10.2337/db18-1235-P.

  16. Shimizu M, Suzuki K, Kato K, Jojima T, Iijima T, Murohisa T. Evaluation of the effects of dapagliflozin, a sodium-glucose co-transporter-2 inhibitor, on hepatic steatosis and fibrosis using transient elastography in patients with type 2 diabetes and non-alcoholic fatty liver disease. Diabetes Obes Metab. 2019;21(2):285–92.

    Article  CAS  Google Scholar 

  17. Itani T, Ishihara T. Efficacy of canagliflozin against nonalcoholic fatty liver disease: a prospective cohort study. Obes Sci Prac. 2018;4(5):477–82.

    Article  Google Scholar 

  18. Seko Y, Sumida Y, Sasaki K, Itoh Y, Iijima H, Hashimoto T. Effects of canagliflozin, an SGLT2 inhibitor, on hepatic function in Japanese patients with type 2 diabetes mellitus: pooled and subgroup analyses of clinical trials. J Gastroenterol. 2018;53(1):140–51.

    Article  CAS  Google Scholar 

  19. Scheen AJ. Effect of sodium-glucose cotransporter type 2 inhibitors on liver fat in patients with type 2 diabetes: hepatic beyond cardiovascular and renal protection? Ann Transl Med. 2018;6(Suppl 1):S68. https://doi.org/10.21037/atm.2018.10.39.

    Article  CAS  PubMed  PubMed Central  Google Scholar 

  20. Seko Y, Sumida Y, Tanaka S, Mori K, Taketani H, Ishiba H. Effect of sodium glucose cotransporter 2 inhibitor on liver function tests in Japanese patients with non-alcoholic fatty liver disease and type 2 diabetes mellitus. Hepatol Res. 2017;47(10):1072–8.

    Article  CAS  Google Scholar 

  21. Aso Y, Kato K, Sakurai S, Kishi H, Shimizu M, Jojima T. Impact of dapagliflozin, an SGLT2 inhibitor, on serum levels of soluble dipeptidyl peptidase-4 in patients with type 2 diabetes and non-alcoholic fatty liver disease. Int J Clin Pract. 2019;73: e13335. https://doi.org/10.1111/ijcp.13335.

    Article  CAS  PubMed  Google Scholar 

  22. Tobita H, Sato S, Miyake T, Ishihara S, Kinoshita Y. Effects of dapagliflozin on body composition and liver tests in patients with nonalcoholic steatohepatitis associated with type 2 diabetes mellitus: a prospective, open-label, uncontrolled study. Curr Ther Res. 2017;87:13–9.

    Article  CAS  Google Scholar 

  23. Raj H, Durgia H, Palui R, Kamalanathan S, Selvarajan S, Kar SS, Sahoo J. SGLT-2 inhibitors in non-alcoholic fatty liver disease patients with type 2 diabetes mellitus: a systematic review. World J Diabetes. 2019;10(2):114.

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

Authors

Corresponding author

Correspondence to Saba Tariq.

Ethics declarations

Ethics approval

Ethical approval is obtained from the Institutional Review Board of Sheikh Zayed Medical College, Rahim Yar Khan via letter no:1351/IRB/SZMC/SZH.

Consent to participate

Written informed consent was obtained.

Conflict of interest

The authors declare no competing interests.

Additional information

Publisher's note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

Rights and permissions

Reprints and permissions

About this article

Check for updates. Verify currency and authenticity via CrossMark

Cite this article

Hussain, M., Babar, M.Z.M., Tariq, S. et al. Therapeutic outcome of dapagliflozin on various parameters in non-alcoholic fatty liver disease (NAFLD) patients. Int J Diabetes Dev Ctries 42, 290–296 (2022). https://doi.org/10.1007/s13410-021-00980-2

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s13410-021-00980-2

Keywords

Navigation